China's liquid biopsy industry is gaining momentum as demand grows for early cancer detection and less invasive diagnostic methods. Market Research Future estimates that the market will increase from USD 704 million in 2025 to USD 1.915 billion by 2035, reflecting a 10.53% CAGR.

Advances in genomic technologies are playing an important role in market development. Next-generation sequencing and digital PCR can provide detailed information from small amounts of biological material, while artificial intelligence and machine learning are being incorporated to improve analysis and diagnostic efficiency.

The market is mainly focused on oncology, with cancer diagnosis accounting for the largest application segment. Treatment monitoring is also gaining importance as liquid biopsy can provide information about treatment response and changes in tumor characteristics. Blood remains the primary sample source, while urine-based testing is developing as an additional option.

Hospitals currently represent the largest end-use segment because of their patient volumes and established diagnostic infrastructure. Diagnostic laboratories are expanding rapidly as they invest in specialized testing capabilities and respond to rising demand for accurate molecular diagnostics.

Looking ahead, the market could benefit from personalized medicine, portable testing devices, advanced biomarker analysis, and collaborations between biotechnology companies and healthcare providers. These developments may make liquid biopsy more accessible and useful across different stages of cancer management.

Discover emerging opportunities with in-depth research reports:

Companion Animal Healthcare Market Share

Blood Plasma Derivatives Market Trends

Migraine Drugs Market Growth

Optical Genome Mapping Market Demand

Homeopathy Product Market Volume